Repligen Corporation
RGEN
Clasificación en acciones
#1863
Repligen Corporation specializes in the creation and distribution of advanced... Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Precio por acción
$179.36
Última sincronización: 2026-10-20
Capitalización bursátil
$11.39B
Cambio (1 día)
1.66%
Cambio (1 año)
14.42%
País
US
Comercio Repligen Corporation (RGEN)
Categoría
Healthcare
Ratio P/E de Repligen Corporation (RGEN)
Ratio P/E al October 2026 TTM: 240.81
Según los últimos informes financieros y el precio de las acciones de Repligen Corporation, el P/E actual (TTM) de la empresa es 240.81. Al final de 2023, la empresa tenía un P/E de 281.45.
Historial del ratio P/E de Repligen Corporation desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 240.81 | -176.31% |
| 2024 | -315.57 | -212.13% |
| 2023 | 281.45 | 457.38% |
| 2022 | 50.49 | -55.54% |
| 2021 | 113.57 | -32.42% |
| 2020 | 168.06 | -19.53% |
| 2019 | 208.85 | 50.35% |
| 2018 | 138.91 | 183.93% |
| 2017 | 48.92 | -44.77% |
| 2016 | 88.58 | -11.01% |
| 2015 | 99.54 | 26.39% |
| 2014 | 78.76 | 193.43% |
| 2013 | 26.84 | 95.70% |
| 2012 | 13.71 | -100.52% |
| 2011 | -2.65K | 8,512.40% |
| 2010 | -30.72 | -219.05% |
| 2009 | 25.81 | 544.33% |
| 2008 | 4.01 | -103.71% |
| 2007 | -107.95 | -167.49% |
| 2006 | 159.95 | -1,033.81% |
| 2005 | -17.13 | 81.87% |
| 2004 | -9.42 | -65.88% |
| 2003 | -27.60 | 18.19% |
| 2002 | -23.35 | 61.51% |
| 2001 | -14.46 | -73.38% |
| 2000 | -54.32 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 47.48 | -80.28% |
US
|
|
| 27.43 | -88.61% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -76.37% |
US
|
|
| - | - |
CH
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.